ABBV vs HON: Which Is the Better Buy?
Side-by-side comparison of AbbVie Inc. and Honeywell International Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-04-29.
AbbVie Inc. · Healthcare
$197.69
+6.3% upside to fair value
Grade C
High Quality
VS
Honeywell International Inc. · Industrials
$213.17
-14.5% upside to fair value
Grade D
QuantHub Verdict
ABBV has more upside to fair value
(+6.3%).
HON trades at a lower forward P/E
(33.0x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
ABBV |
HON |
| Current Price |
$197.69 |
$213.17 |
| Fair Value Estimate |
$210.22 |
$182.35 |
| Upside to Fair Value |
+6.3%
|
-14.5%
|
| Market Cap |
$349.7B |
$135.1B |
| Forward P/E |
83.3x
|
33.0x
|
| EV / EBITDA |
23.4x
|
23.9x
|
| Price / Sales |
5.7x
|
3.7x
|
| Price / FCF |
18.7x
|
32.4x
|
| Revenue Growth YoY |
+10.0%
|
-6.9%
|
| Gross Margin |
70.2%
|
36.9%
|
| Operating Margin |
26.7%
|
14.9%
|
| Return on Equity |
-361.6%
|
23.6%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
5.35%
|
3.09%
|
| Analyst Consensus |
Strong Buy
|
Buy
|
Investment Thesis
AbbVie Inc. is a leading healthcare company specializing in drug manufacturing with a strong focus on immunology, neuroscience, oncology, and aesthetics. The company benefits from a durable competitive moat driven by blockbuster drugs such as Skyrizi and Rinvoq, which are experiencing rapid growth and offsetting declines from Humira due to biosimilar competition. Despite a high trailing and forwa…
Honeywell International Inc. is a diversified industrial conglomerate operating across Aerospace Technologies, Building Automation, Process Automation and Technology, and Safety and Productivity Solutions. The company benefits from a strong leadership team with deep internal experience and a history of strategic acquisitions that have expanded its portfolio into high-growth areas such as aerospac…
Accumulation Zones
| Metric |
ABBV |
HON |
| Zone Low |
$157.66 |
$136.76 |
| Zone High |
$178.69 |
$155.00 |
| In Buy Zone? |
No
|
No
|